# Pharma focus on weight-loss drugs could put insulin supply at risk, experts warn

https://mins.news/en/item/137267

- The Guardian, 2026-11-10 13:00 UTC
- Health
- Original: https://www.theguardian.com/business/2026/nov/10/pharma-firms-weight-loss-drugs-insulin-glp-1-ozempic-mounjaro

> The Access to Medicine Foundation warns that pharmaceutical companies’ rush into GLP-1 weight-loss drugs could draw attention away from insulin and other diabetes treatments. Its report says many people in poorer countries cannot obtain basic insulin, while GLP-1 drugs remain inaccessible in many markets. Higher profits from weight-loss treatments could also put insulin supply at risk.

## Related coverage

- [FDA orders new eye-condition warning for Ozempic, Wegovy and other GLP-1 drugs](https://mins.news/en/video/137832) — ABC News, 2026-11-10
- [US regulator warns of potential eye-condition risk linked to GLP-1 drugs](https://mins.news/en/item/135928) — CNN, 2026-11-09
- [US FDA orders new eye-risk warnings for Ozempic and Zepbound](https://mins.news/en/item/135774) — Reuters, 2026-11-09
